# Milrinone Versus Dobutamine in Critically Ill Patients

Study · id `cardio:ct-nct03207165` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03207165](<https://clinicaltrials.gov/study/NCT03207165>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT03207165

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 192 participants.

## Technical summary

Registry record NCT03207165. Randomized; quadruple masking; primary purpose treatment. Start 2017-08-30 (actual); primary completion 2020-06-12 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 192 participants (enrolled count; ClinicalTrials.gov record NCT03207165, source copy `cardio:ctgov-nct03207165-2020-06-30`, retrieved 2026-10-31)
- Started: 2017-08-30 (actual) (ClinicalTrials.gov record NCT03207165, source copy `cardio:ctgov-nct03207165-2020-06-30`, retrieved 2026-10-31)
- Primary completion: 2020-06-12 (actual) (ClinicalTrials.gov record NCT03207165, source copy `cardio:ctgov-nct03207165-2020-06-30`, retrieved 2026-10-31)
- Completion: 2020-06-12 (actual) (ClinicalTrials.gov record NCT03207165, source copy `cardio:ctgov-nct03207165-2020-06-30`, retrieved 2026-10-31)
- Countries: Canada (ClinicalTrials.gov record NCT03207165, source copy `cardio:ctgov-nct03207165-2020-06-30`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03207165-2020-06-30`, retrieved 2026-10-31)

## The registry's words

- Brief title: Milrinone Versus Dobutamine in Critically Ill Patients
- Condition: Low Cardiac Output Syndrome
- Condition: Cardiogenic Shock
- Condition: Acute Coronary Syndrome
- Condition: Pulmonary Edema
- Intervention (Drug): Milrinone
- Intervention (Drug): Dobutamine
- Lead sponsor: Ottawa Heart Institute Research Corporation
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry condition terms include this condition: Cardiogenic shock (`cardio:cardiogenic-shock`)
- Registry intervention name matches this record: Milrinone (`cardio:milrinone`)
- Registry intervention name matches this record: Dobutamine (`cardio:dobutamine`)
- Registry lists this organization as the lead sponsor: Ottawa Heart Institute Research Corporation (`cardio:org-ottawa-heart-institute-research-corporation`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Milrinone as Compared with Dobutamine in the Treatment of Cardiogenic Shock (`cardio:pubmed-34347952`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Impact of baseline beta-blocker use on inotrope response and clinical outcomes in cardiogenic shock: a subgroup analysis of the DOREMI trial (`cardio:pubmed-34376218`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Implications of Myocardial Infarction on Management and Outcome in Cardiogenic Shock (`cardio:pubmed-34713704`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Lactate Clearance as a Surrogate for Mortality in Cardiogenic Shock: Insights From the DOREMI Trial (`cardio:pubmed-35261289`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 39cfb2890144146f40be72c6776801befc5ac2caa80cc478290d93a950ef5fd3
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
